CSIMarket Company Name, Ticker, Industry, else..
 
Promis Neurosciences inc   (NASDAQ: PMN)
Other Ticker:  
 
 
Price: $0.5830 $-0.02 -3.333%
Day's High: $0.62 Week Perf: -1.98 %
Day's Low: $ 0.56 30 Day Perf: -16.71 %
Volume (M): 25 52 Wk High: $ 2.37
Volume (M$): $ 15 52 Wk Avg: $1.18
Open: $0.62 52 Wk Low: $0.10



 Market Capitalization (Millions $) 15
 Shares Outstanding (Millions) 25
 Employees 18
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Promis Neurosciences Inc
Promis Neurosciences Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for the treatment of neurodegenerative diseases. The company's main mission is to discover, develop, and deliver therapeutics that target the underlying causes and progression of these diseases. Promis Neurosciences is known for its expertise in neurodegeneration and its ability to identify novel drug candidates that have the potential to improve patients' lives. The company is committed to advancing its pipeline of drugs and is dedicated to making a significant impact in the field of neurology.


   Company Address: Suite 200, 1920 Yonge Street Toronto 0 ON
   Company Phone Number: 847-6898   Stock Exchange / Ticker: NASDAQ PMN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BHVN        2.15% 
CRNX        2.9% 
ITCI        0.14% 
MTVA   -4.05%    
PTIX   -4.09%    
SPRB   -39.35%    
• View Complete Report
   



Announcement

?Unlocking Hope ProMIS Neurosciences? Strategic Advances in the Fight Against Neurodegenerative Diseases?,

Published Mon, Mar 31 2025 12:40 PM UTC

Unlocking Hope: ProMIS Neurosciences? Strategic Advances in the Fight Against Neurodegenerative Diseases In an era marked by advancing scientific frontiers, ProMIS Neurosciences Inc. has consistently fortified its position as a pioneering entity in the realm of biotechnology. In light of recent developments, the company has demonstrated not only fiscal resilience but also an...
Announcement

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Disea...

Published Mon, Mar 24 2025 11:21 AM UTC

ProMIS Neurosciences: Promising Advances in Antibody Therapeutics Amidst Competitive Revenue ChallengesIn a pivotal moment for the field of neurodegenerative disease research, ProMIS Neurosciences has recently showcased groundbreaking preclinical data regarding its antibody therapeutics and vaccines at the prestigious Alzheimer s Disease/Parkinson s Disease 2025 Internation...
Announcement

ProMIS Neurosciences Pioneering Antibody Therapeutics for Neurodegenerative Diseases

Published Mon, Jan 13 2025 3:35 PM UTC

Neurodegenerative diseases such as Alzheimer s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) pose significant challenges in both clinical treatment and research. As these diseases progress, the toxic accumulation of misfolded proteins contributes to neuronal degeneration and loss of function. ProMIS Neurosciences Inc., a clinical-stage...
Announcement

Navigating Challenges and Opportunities ProMIS Neurosciences to Share Insights at Evercore HealthCONx amidst Financ...

Published Tue, Nov 26 2024 12:00 PM UTC

ProMIS Neurosciences Inc., a clinical-stage biotechnology company dedicated to developing antibody therapeutics aimed at toxic misfolded proteins associated with neurodegenerative diseases, is expected to participate in the 7th Annual Evercore HealthCONx Conference. This prestigious event will take place in Coral Gables, Florida, on December 3, 2024. Neil Warma, the Chief Ex...
Announcement

ProMIS Neurosciences Advances Alzheimers Research with PMN310 Unveiling Promising Preclinical Data and Clinical Prog...

Published Thu, Sep 12 2024 11:00 AM UTC

In a significant leap forward in the fight against neurodegenerative diseases, ProMIS Neurosciences Inc. (Nasdaq: PMN), a pioneering biotechnology firm, is garnering attention with its innovative approach to targeting toxic misfolded proteins. At the forefront of this initiative is their lead product candidate, PMN310, which aims to address Alzheimer s disease (AD) through a...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com